Since the inception of radionuclide therapies by John Lawrence and Saul Hertz over 80 years ago, little has changed in dosing strategies. Therapeutic radionuclides are still typically administered at fixed intervals or as a single treatment, with little regard to an individual patient’s disease characteristics and uptake.
Personalized treatment using radiation dosimetry has been proposed to improve outcomes, but progress has been limited by technical challenges, lack of prospective clinical trial data, and reimbursement and sustainability issues.
The Foundation for the National Institutes of Health Biomarkers Consortium has recently launched the Precision Dosimetry Imaging Biomarker (PDIB) project, an international, consortium-based initiative focused on solving the technical issues that limit the effective use of dosimetry-informed therapy. Launched in April 2025 and funded by industry partners, the project aims to enable reliable, reproducible, and standardized dosimetry for targeted radionuclide therapies.
Read the full JNM article here.